BR112021022089A2 - Materiais e métodos para modulação da imunidade mediada por células t - Google Patents
Materiais e métodos para modulação da imunidade mediada por células tInfo
- Publication number
- BR112021022089A2 BR112021022089A2 BR112021022089A BR112021022089A BR112021022089A2 BR 112021022089 A2 BR112021022089 A2 BR 112021022089A2 BR 112021022089 A BR112021022089 A BR 112021022089A BR 112021022089 A BR112021022089 A BR 112021022089A BR 112021022089 A2 BR112021022089 A2 BR 112021022089A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- antibodies
- modulating
- cell
- materials
- Prior art date
Links
- 230000024932 T cell mediated immunity Effects 0.000 title abstract 2
- 239000000463 material Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
materiais e métodos para modulação da imunidade mediada por células t. são descritos anticorpos anti-trgv9 ou fragmento de ligação a antígeno dos mesmos. são descritos, também, ácidos nucleicos que codificam os anticorpos, composições que compreendem os anticorpos, métodos de produção dos anticorpos e métodos de uso dos anticorpos para tratamento ou prevenção de doenças, como câncer.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962844959P | 2019-05-08 | 2019-05-08 | |
US201962844970P | 2019-05-08 | 2019-05-08 | |
US201962844995P | 2019-05-08 | 2019-05-08 | |
US201962844966P | 2019-05-08 | 2019-05-08 | |
US201962844976P | 2019-05-08 | 2019-05-08 | |
PCT/US2020/031749 WO2020227457A1 (en) | 2019-05-08 | 2020-05-07 | Materials and methods for modulating t cell mediated immunity |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021022089A2 true BR112021022089A2 (pt) | 2022-02-08 |
Family
ID=73051172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021022089A BR112021022089A2 (pt) | 2019-05-08 | 2020-05-07 | Materiais e métodos para modulação da imunidade mediada por células t |
Country Status (21)
Country | Link |
---|---|
US (2) | US11667712B2 (pt) |
EP (1) | EP3965818A4 (pt) |
JP (1) | JP2022533538A (pt) |
KR (1) | KR20220017892A (pt) |
CN (1) | CN113966231A (pt) |
AU (1) | AU2020267504A1 (pt) |
BR (1) | BR112021022089A2 (pt) |
CA (1) | CA3139508A1 (pt) |
CL (1) | CL2021002905A1 (pt) |
CO (1) | CO2021015998A2 (pt) |
CR (1) | CR20210548A (pt) |
DO (1) | DOP2021000229A (pt) |
EC (1) | ECSP21087921A (pt) |
IL (1) | IL287817A (pt) |
JO (1) | JOP20210297A1 (pt) |
MA (1) | MA55903A (pt) |
MX (1) | MX2021013532A (pt) |
PE (1) | PE20220763A1 (pt) |
SG (1) | SG11202112021QA (pt) |
TW (1) | TW202108618A (pt) |
WO (1) | WO2020227457A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210284731A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
JP2024507937A (ja) | 2021-02-26 | 2024-02-21 | ラヴァ・セラピューティクス・エヌ・ヴイ | Cd123及びガンマデルタt細胞受容体に結合する抗体 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1461082A4 (en) | 2001-12-03 | 2006-06-28 | Abgenix Inc | ANTIBODIES AGAINST THE TUMOR ANTIGEN OF CARBON IX ANHYDRASE (CA IX) |
JP2008511337A (ja) | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
ES2592271T3 (es) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos |
DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
AR060070A1 (es) | 2006-03-24 | 2008-05-21 | Merck Patent Gmbh | Dominios proteicos heterodimericos obtenidos por ingenieria |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
US20090155275A1 (en) | 2007-07-31 | 2009-06-18 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20100261620A1 (en) | 2008-10-14 | 2010-10-14 | Juan Carlos Almagro | Methods of Humanizing and Affinity-Maturing Antibodies |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
BR112012004777A2 (pt) * | 2009-09-03 | 2019-09-24 | Genentech Inc | métodos para tratar diagnósticar e monitorar artrite reumatoide |
KR101930964B1 (ko) | 2010-04-20 | 2018-12-19 | 젠맵 에이/에스 | 이종이량체 항체 fc-함유 단백질 및 그의 생산 방법 |
US9328166B2 (en) | 2010-08-05 | 2016-05-03 | Anaptysbio, Inc. | Antibodies directed against IL-17 |
BR112013011811A2 (pt) | 2010-11-05 | 2023-02-23 | Zymeworks Inc | Modelo de anticorpo heterodimérico estável com mutações no domínio fc |
LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
RS62689B1 (sr) | 2011-11-04 | 2021-12-31 | Zymeworks Inc | Dizajn stabilnog heterodimernog antitela sa mutacijama u fc domenu |
SI2794658T1 (sl) | 2011-12-19 | 2017-05-31 | Synimmune Gmbh | Bispecifična molekula protitelesa |
AU2014339926B2 (en) * | 2013-10-25 | 2018-02-08 | Board Of Regents, The University Of Texas System | Polyclonal gamma delta T cells for immunotherapy |
CA2948812A1 (en) * | 2014-04-10 | 2015-10-15 | Stichting Vumc | Immunoglobulins binding human v.gamma.9v.delta.2 t cell receptors |
EP3303394B1 (en) | 2015-05-29 | 2020-04-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
US11117963B2 (en) | 2016-12-26 | 2021-09-14 | Kyowa Hakko Kirin Co., Ltd. | Antibody which binds to myelin oligodendrocyte glycoprotein |
US11236145B2 (en) * | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
US10519236B2 (en) * | 2018-01-23 | 2019-12-31 | New York University | Antibodies specific to delta 1 chain of T cell receptor |
US20220306739A1 (en) | 2020-02-27 | 2022-09-29 | Janssen Biotech, Inc. | Materials and methods for modulating an immune response |
US20210284731A1 (en) | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
CN116390950A (zh) | 2020-10-28 | 2023-07-04 | 詹森生物科技公司 | 用于调节δγ链介导的免疫的组合物和方法 |
-
2020
- 2020-05-07 BR BR112021022089A patent/BR112021022089A2/pt unknown
- 2020-05-07 MX MX2021013532A patent/MX2021013532A/es unknown
- 2020-05-07 US US16/869,401 patent/US11667712B2/en active Active
- 2020-05-07 CR CR20210548A patent/CR20210548A/es unknown
- 2020-05-07 JO JOP/2021/0297A patent/JOP20210297A1/ar unknown
- 2020-05-07 SG SG11202112021QA patent/SG11202112021QA/en unknown
- 2020-05-07 PE PE2021001851A patent/PE20220763A1/es unknown
- 2020-05-07 CA CA3139508A patent/CA3139508A1/en active Pending
- 2020-05-07 TW TW109115171A patent/TW202108618A/zh unknown
- 2020-05-07 AU AU2020267504A patent/AU2020267504A1/en active Pending
- 2020-05-07 MA MA055903A patent/MA55903A/fr unknown
- 2020-05-07 WO PCT/US2020/031749 patent/WO2020227457A1/en unknown
- 2020-05-07 KR KR1020217036132A patent/KR20220017892A/ko unknown
- 2020-05-07 CN CN202080043002.2A patent/CN113966231A/zh active Pending
- 2020-05-07 JP JP2021565723A patent/JP2022533538A/ja active Pending
- 2020-05-07 EP EP20801607.1A patent/EP3965818A4/en active Pending
-
2021
- 2021-11-03 IL IL287817A patent/IL287817A/en unknown
- 2021-11-04 CL CL2021002905A patent/CL2021002905A1/es unknown
- 2021-11-04 DO DO2021000229A patent/DOP2021000229A/es unknown
- 2021-11-26 CO CONC2021/0015998A patent/CO2021015998A2/es unknown
- 2021-12-03 EC ECSENADI202187921A patent/ECSP21087921A/es unknown
-
2023
- 2023-04-25 US US18/306,401 patent/US20240150464A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3965818A4 (en) | 2023-05-31 |
JP2022533538A (ja) | 2022-07-25 |
ECSP21087921A (es) | 2022-01-31 |
AU2020267504A1 (en) | 2021-12-02 |
US11667712B2 (en) | 2023-06-06 |
KR20220017892A (ko) | 2022-02-14 |
DOP2021000229A (es) | 2022-07-31 |
US20240150464A1 (en) | 2024-05-09 |
MA55903A (fr) | 2022-03-16 |
CL2021002905A1 (es) | 2022-06-17 |
SG11202112021QA (en) | 2021-11-29 |
MX2021013532A (es) | 2022-02-11 |
PE20220763A1 (es) | 2022-05-16 |
IL287817A (en) | 2022-01-01 |
TW202108618A (zh) | 2021-03-01 |
US20210032338A1 (en) | 2021-02-04 |
CO2021015998A2 (es) | 2021-12-10 |
EP3965818A1 (en) | 2022-03-16 |
CN113966231A (zh) | 2022-01-21 |
CR20210548A (es) | 2022-02-11 |
CA3139508A1 (en) | 2020-11-12 |
JOP20210297A1 (ar) | 2023-01-30 |
WO2020227457A1 (en) | 2020-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
PH12019501973A1 (en) | Anti-phf-tau antibodies and uses thereof | |
MX2020009326A (es) | Anticuerpos anti-claudina 18.2 y usos de los mismos. | |
BR112019004998A2 (pt) | anticorpos anti-pd-1(cd279) | |
BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
BR112018074468A2 (pt) | anticorpos anti-cd40 e suas utilizações | |
BR112017003194B8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição | |
JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
BR112021017801A2 (pt) | Anticorpos biespecíficos anti-vbeta17/anti-cd123 | |
WO2019217145A8 (en) | Anti-dll3 antibodies and uses thereof | |
BR112022003740A2 (pt) | Anticorpos anti-cd96 e métodos de uso dos mesmos | |
BR112021013397A2 (pt) | Anticorpos anti-tigit | |
BR112018072118A2 (pt) | anticorpos de interferona beta e usos dos mesmos | |
BR112022020410A2 (pt) | Anticorpos anti-phf-tau e usos dos mesmos | |
BR112021022089A2 (pt) | Materiais e métodos para modulação da imunidade mediada por células t | |
MX2020009522A (es) | Anticuerpos anti-folato del receptor 1 y usos de los mismos. | |
EA201991845A1 (ru) | Фармацевтические комбинации, содержащие антитело к ly75 | |
WO2021173896A8 (en) | Materials and methods for modulating an immune response | |
BR112023019546A2 (pt) | Anticorpos anti-tau e usos dos mesmos | |
CL2021001607A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
BR112022012731A2 (pt) | Anticorpo anti-ox40 e uso do mesmo | |
BR112022001336A2 (pt) | Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo | |
CO2023000557A2 (es) | Anticuerpos y métodos para tratar enfermedades asociadas a claudina | |
MX2023002948A (es) | Métodos y composiciones para modular la inmunidad mediada por cadena beta. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11U | Patent application definitively rejected as a later application filed via pct claims it as a priority [chapter 11.21 patent gazette] |
Free format text: ARQUIVADO DEFINITIVAMENTE ESTE PEDIDO DE PATENTE, UMA VEZ QUE FOI ADMITIDO NA FASE NACIONAL BRASILEIRA O PEDIDO (112022017142-0) QUE O REIVINDICA COMO PRIORIDADE. |
|
B11N | Dismissal: publication cancelled [chapter 11.14 patent gazette] |
Free format text: ANULACAO DO DESPACHO DE ARQUIVAMENTO DEFINITIVO DO PEDIDO (DESPACHO 11.21) POR TER SIDO INDEVIDO, TENDO EM VISTA A NECESSIDADE DE AVALIACAO DO CONTEUDO DOS PEDIDOS PELA AREA TECNICA. |